Companies›Healthcare›Healthcare›Healthcare Services
NSE:LOTUSEYE

LOTUS EYE HOSP & INST L

Healthcare › Healthcare Services
₹109.32
at close · 28 Oct 2026
▼ 1.68 (-1.51%)

Latest filings

  1. RTA compliance certificate for quarter ended September 2026 · Compliance
  2. Trading Window closure ahead of Q2 FY26 results · Compliance
  3. Lotus Eye Hospital AGM 2026: All 4 resolutions passed · Board & Shareholder Meetings
All filings ↓
Ask Nexa about LOTUS EYE HOSP & INST L

Snapshot

What the business is, and whether it's a good one at a fair price.

A Healthcare Services company listed on NSE and BSE, reporting revenue of ₹57 Cr over the trailing twelve months.

Market Cap
₹227 Cr
P / E (TTM)
1366.5×
EV / EBITDA
39.2×
Div Yield
0.01%
Growth
10.7%▲
Revenue 5y CAGR
PAT -44.8% · EBITDA +0.8%
Quality
6.8%·
ROCE (5y median)
ROE 4.9% (5y median) · margin 8.5%
Leverage
0.19·
Debt / Equity · low
Net debt ₹9.62 Cr
Revenue FY21→FY26
1.7×▲
Margin −4.7 pts
₹32 Cr → ₹54 Cr
Cash conversion
2.09×▲
Operating cash ÷ profit · 5 yrs
₹23 Cr on ₹11 Cr
Moves on a normal day
1.53%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 29 Hospital peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#30/30
P/B#6/24
ROCE#28/30
ROE#24/24
Debt / Equity#11/24
EBITDA margin#20/24
Revenue growth#8/23
Profit growth#9/21

Scorecard

Measured from the filed financials, judged against its Hospital peers · as of FY26 — not investment advice

Strengths
Over 5 years it reported ₹11 Cr of profit and ₹23 Cr of operating cash — 2.09×
Profit is converting into cash
Concerns
Profit shrinking over 5 years (−45% a year)
Erratic profits — up in only 2 of the last 5 years
Returns on capital 6.8% (5-year median)
#28 of 30 in Hospital on the latest reported figures · down from 3.9% in FY21

Charts

How has the market priced it — with filings on the timeline?

LOTUSEYE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from LOTUS EYE HOSP & INST L's filed financials and exchange disclosures

What does LOTUS EYE HOSP & INST L do?

LOTUS EYE HOSP & INST L is a Healthcare Services company listed on NSE and BSE, trading under the symbol LOTUSEYE.

Is LOTUS EYE HOSP & INST L profitable?

Yes. Over the trailing twelve months LOTUS EYE HOSP & INST L reported a net profit of ₹0.15 Cr on revenue of ₹57 Cr.

Does LOTUS EYE HOSP & INST L pay a dividend?

Yes. The dividend yield is 0.01% at the current price. It paid out 15% of its profit as dividend in FY26.

Is LOTUS EYE HOSP & INST L debt-free?

No. It reported borrowings of ₹11 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹9.62 Cr after cash. Debt stands at 0.19× equity. That is lower than 57% of its 24 Hospital peers.

Is LOTUS EYE HOSP & INST L expensive compared with its peers?

On trailing P/E, LOTUS EYE HOSP & INST L ranks 30 of 30 in Hospital — cheaper than 0% of them, against an industry median of 42.0×. This is a position, not a valuation judgement.

How much does the LOTUS EYE HOSP & INST L share price move in a day?

On a typical session LOTUS EYE HOSP & INST L moves 1.53% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

Where can I track LOTUS EYE HOSP & INST L's announcements?

Every NSE and BSE filing by LOTUS EYE HOSP & INST L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.